Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

Université Laval

$150,000.00

New antiviral agents against herpes simplex viruses

EF 2009-10

Résumé
Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are responsible for frequent orolabial and genital infections. Drugs of choice to treat these infections include acyclovir and penciclovir and their respective prodrugs valacyclovir and famciclovir. The emergence of resistance to these drugs is frequent in immunocompromised patients. By using computer-generated 3D modelling and virtual screening of a large bank of compounds, we have identified some drugs with high affinity to the HSV DNA polymerase which are active against HSV strains resistant to first line agents in vitro. In this research project, we propose to move ahead the development of the new lead compound by elucidating its mechanism of action against HSV. We will determine its selectivity for the HSV DNA polymerase and its toxicity for stationary and dividing cultured cells. We will also generate resistant mutants and evaluate cross-resistance with current antiviral drugs. Moreover, we will evaluate the efficacy of our lead compound in relevant mouse models of HSV-1 cutaneous infection and of HSV encephalitis. With these data in hand, we will be able to attract pharmaceutical companies with a virology portfolio to license our patent rights. These companies have all relevant assets to develop the lead compound for the benefit of human health in a timely manner.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
194442
Name
Boivin Guy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
New antiviral agents against herpes simplex viruses
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Animal; Antiviral; Dna Polymerase; Herpes Simplex Virus; Modeling; Resistance
Abstract
Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are responsible for frequent orolabial and genital infections. Drugs of choice to treat these infections include acyclovir and penciclovir and their respective prodrugs valacyclovir and famciclovir. The emergence of resistance to these drugs is frequent in immunocompromised patients. By using computer-generated 3D modelling and virtual screening of a large bank of compounds, we have identified some drugs with high affinity to the HSV DNA polymerase which are active against HSV strains resistant to first line agents in vitro. In this research project, we propose to move ahead the development of the new lead compound by elucidating its mechanism of action against HSV. We will determine its selectivity for the HSV DNA polymerase and its toxicity for stationary and dividing cultured cells. We will also generate resistant mutants and evaluate cross-resistance with current antiviral drugs. Moreover, we will evaluate the efficacy of our lead compound in relevant mouse models of HSV-1 cutaneous infection and of HSV encephalitis. With these data in hand, we will be able to attract pharmaceutical companies with a virology portfolio to license our patent rights. These companies have all relevant assets to develop the lead compound for the benefit of human health in a timely manner.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boivin, Guy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~